<!doctype html>
<html lang="en">
<head>
  <meta charset="utf-8" />
  <meta name="viewport" content="width=device-width, initial-scale=1" />
  <title>MDT Report</title>
  <style>
    :root {
      --border: #e5e7eb;
      --muted: #6b7280;
      --bg: #ffffff;
      --card: #ffffff;
      --soft: #f7f7f8;
      --accent: #2563eb;
    }
    body { font-family: -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif; margin: 24px; background: var(--bg); }
    h1 { font-size: 20px; margin: 0 0 12px 0; }
    h2 { font-size: 16px; margin: 0 0 10px 0; }
    h3 { font-size: 14px; margin: 10px 0 6px 0; }
    .meta { color: var(--muted); font-size: 13px; margin-bottom: 14px; }
    .cols { display: grid; grid-template-columns: 1fr 1fr; gap: 12px; }
    .card { border: 1px solid var(--border); border-radius: 12px; padding: 12px 14px; background: var(--card); }
    details { border: 1px solid var(--border); border-radius: 12px; padding: 10px 12px; background: var(--card); }
    summary { cursor: pointer; font-weight: 600; }
    pre { white-space: pre-wrap; word-wrap: break-word; background: var(--soft); padding: 12px; border-radius: 10px; overflow-x: auto; }
    .mono { font-family: ui-monospace, SFMono-Regular, Menlo, Monaco, Consolas, "Liberation Mono", "Courier New", monospace; }
    .mt { margin-top: 12px; }
    .hint { color: var(--muted); font-size: 12px; margin-top: 6px; }
    .warn { color: #b45309; font-weight: 600; }
    table.grid { width: 100%; border-collapse: collapse; font-size: 13px; }
    table.grid th, table.grid td { border: 1px solid var(--border); padding: 8px; vertical-align: top; }
    table.grid th { background: #f3f4f6; text-align: left; }
  </style>
</head>
<body>
  <h1>OMGs / MDT Report</h1>
  <div class="meta">
    <div><b>Timestamp</b>: 2026-01-17_22-35-42</div>
  </div>

  <div class="cols mt">
    <div class="card">
      <h2>Final MDT Output</h2>
      <pre>- If post-op CT/PET shows unresectable residual disease, then adjust management from adjuvant-intent systemic therapy to primary systemic ± local palliation.  
- If germline/somatic BRCA or HRD testing returns positive, then adjust management from chemo-only strategy to chemo followed by targeted maintenance.  
- If gastric primary is confirmed dominant driver on integrated pathology/MDT, then adjust management from ovarian-primary pathway to upper-GI–oriented systemic strategy.  
- If post-op CA125 and imaging normalize and performance status is good, then adjust management from palliative expectation to aggressive consolidation plus structured surveillance.  
- If significant chemo-induced cytopenias or organ dysfunction recur, then adjust management from full-intensity systemic therapy to dose-modified or alternative-schedule systemic control.</pre>
    </div>
    <div class="card">
      <h2>Question (raw)</h2>
      <div class="hint">Original user question for observability (passed from main via args.question_raw).</div>
      <pre>卵巢恶性肿瘤：子宫内膜样腺瘤：盆腔肿瘤：2025.5.27 petct：1. 双附件占位，考虑卵巢 癌，肝脏、肝包膜下及 心膈角区、肝 门部、腹膜后淋巴结 转移，腹膜、网膜转移，腹盆腔积液。2.　 头颅 显像未见异常3.双侧颈部 、颌下稍大淋巴结 ，考虑炎症 改变4.慢性阑尾炎5. 腰椎间 膨出。结核感染T细胞检查 ：阴性。胃镜：胃窦病变（待病理）。肠镜： 大致正常。病理诊断： 病理会诊咨询意见:（胃窦，活检）低分化腺癌（失粘附性癌）。原单位免疫组化：MLH1(ES05)（+），MSH6（+），MSH2（+），PMS2（+）补充诊断1：结合免疫组化结果，倾向胃原发腺癌。免疫组化结果（HI25-28648）：PAX8（-），ER（-），PR（-），WT1（-），Claudin 18 (43-14A)（≥75%；2/3+）; 补充报告医生：黄丹;　复诊医生：黄丹;　补充报告日期：2025-06-27 ;报告医生： 毛璐宁 报告日期： 2025/06/07　2025.6.5在全麻下行腹腔镜探查术+女性盆腔肿物活检术+大网膜活检术。2025.6.18.（腹膜肿瘤、大网膜肿瘤）腺癌，正在加做免疫组化进一步辅助诊断。补充诊断1：【补充报告】（腹膜肿瘤、大网膜肿瘤）腺癌，结合免疫组化结果考虑为女生殖系统来源的高级别腺癌，倾向高级别内膜样腺癌。免疫组化结果（HI25-26021）：ER（+），PR（-），P53（部分+），WT1（+），HNF1B（-），NapsinA（-），P16（强+），PAX8（+），CDX-2（-），SATB2（-），CK7（+），CK20（-）; 补充报告医生：张丽;　复诊医生：翁微微;　补充报告日期：2025-06-18 ;下腹部饭后疼痛2025.6.24.予紫杉醇+卡铂行第1次化疗2025.7.13.外院血常规：白细胞：3.17↓　血红蛋白：103↓　血小板：2222025.7.13.外院肿标：CA125:68↑2025.7.13.外院肝肾功能：GLB：36.8↑　A/G:1.10↓2025.6.24.、2025.7.17. 予紫杉醇+卡铂 行2次化疗2025.8.4.外院血常规：白细胞：2.31↓ 血红蛋白：102 ↓ 血小板：124其他未见异常2025.08.26 胃癌根治术+全子宫切除伴双附件（腹式）+大网膜切除术+阑尾切除术+盆底腹膜切除术病理诊断：标本类型:全子宫+双附件+盆底腹膜+肝圆韧带+远端胃+大网膜+阑尾肿瘤大小:左侧：4.8×3.5 ×2.5 cm；右侧：3.5×1.5×0.7cm肿瘤侧别:双侧附件病理类型:高级别腺癌，正在行免疫组化进一步诊断其他部位情况:左输卵管:见癌累及右输卵管:见癌累及子宫内膜:萎缩改变宫颈:见癌累及子宫肌层:未见特殊盆腹腔多部位病灶:（盆底腹膜、大网膜）见癌累及。（肝圆韧带）未见癌累及。其他:（远端胃）低分化腺癌，肿瘤大小2*1.5*1.5cm，浸润至黏膜下层（SM1，浸润深度＜500μm），未见肯定的脉管癌栓及神经侵犯，标本上、下切缘均（-）。Lauren分型：倾向弥漫型。另送（上切缘、下切缘）均阴性。淋巴结（3/25）见癌转移，正在行免疫组化明确类型，其中：小弯淋巴结（3/5），大弯淋巴结（0/8）、幽门上淋巴结（0/6）（第6组）淋巴结（0/1），（第12A组）淋巴结（0/5）。（阑尾）慢性炎。补充诊断1：补充报告：标本类型:全子宫+双附件+盆底腹膜+肝圆韧带+远端胃+大网膜+阑尾肿瘤大小:左侧：4.8×3.5 ×2.5 cm；右侧：3.5×1.5×0.7cm肿瘤侧别:双侧附件病理类型:高级别腺癌伴肿瘤细胞退变，结合临床病史，符合治疗后改变，诊断需考虑高级别内膜样腺癌与高级别浆液性癌，免疫表型不典型（I2025-10475)，必要时可加做分子检测（需来病理科缴费）。其他部位情况:左输卵管:见癌累及右输卵管:见癌累及子宫内膜:萎缩改变宫颈:见癌累及子宫肌层:未见特殊盆腹腔多部位病灶:（盆底腹膜、大网膜）见癌累及。（肝圆韧带）未见癌累及。其他:（远端胃）低分化腺癌，肿瘤大小2*1.5*1.5cm，浸润至黏膜下层（SM1，浸润深度＜500μm），未见肯定的脉管癌栓及神经侵犯，标本上、下切缘均（-）。Lauren分型：倾向弥漫型。另送（上切缘、下切缘）均阴性。淋巴结（3/25）见癌转移，结合免疫组化结果，符合卵巢癌转移，其中：小弯淋巴结（3/5），大弯淋巴结（0/8）、幽门上淋巴结（0/6）（第6组）淋巴结（0/1），（第12A组）淋巴结（0/5）。（阑尾）慢性炎。免疫组化结果（HI25-42710）：远端胃：瘤细胞HER2（0），EBER（-），MLH1(ES05)（+），MSH2（+），MSH6（+），PMS2（+），CDX-2（+），CK20（+），CK7（+），PAX8（-），Ki-67（+60%），E-Cadherin（+），Claudin 18 (43-14A)（-），ER（-）淋巴结：瘤细胞PAX8（+），CDX-2（-），ER（+），WT1（+）; 补充报告医生：曹龄丹;　复诊医生：张萌;　补充报告日期：2025-09-16 ;报告医生： 曹龄丹 报告日期： 2025/09/01病理诊断： 瘤细胞示：ER（部分+），PR（个别+），P53（部分+），WT1（+），Ki-67（+20％），HER2（0），HNF1B（-），NapsinA（-），P16（弥漫+），PAX8（+），IMP3（+），TTF-1（-），GATA3（-）报告医生： 张肖艳 报告日期： 2025/09/04今为术后复查</pre>

      <details class="mt">
        <summary>Case (Structured JSON)</summary>
        <pre>{&quot;CASE_CORE&quot;:{&quot;ADJUVANT_TREATMENT&quot;:{&quot;cycles_or_courses&quot;:&quot;Unknown&quot;,&quot;given&quot;:&quot;Unknown&quot;,&quot;regimens&quot;:[]},&quot;BIOMARKERS&quot;:{&quot;AFP&quot;:&quot;Unknown&quot;,&quot;CA125&quot;:&quot;68 (2025-07-13)&quot;,&quot;HER2&quot;:&quot;0 (IHC)&quot;,&quot;MSI&quot;:&quot;MMR proteins intact (MLH1+, MSH2+, MSH6+, PMS2+)&quot;,&quot;PDL1_CPS&quot;:&quot;Unknown&quot;,&quot;TMB&quot;:&quot;Unknown&quot;},&quot;BRCA1&quot;:&quot;Unknown&quot;,&quot;BRCA2&quot;:&quot;Unknown&quot;,&quot;CURRENT_STATUS&quot;:&quot;Postoperative follow-up&quot;,&quot;DIAGNOSIS&quot;:{&quot;components&quot;:[&quot;peritoneum&quot;,&quot;omentum&quot;,&quot;left ovary&quot;,&quot;right ovary&quot;,&quot;uterus&quot;,&quot;left fallopian tube&quot;,&quot;right fallopian tube&quot;,&quot;appendix&quot;,&quot;distal stomach&quot;,&quot;hepatic ligament&quot;],&quot;histology&quot;:&quot;高级别腺癌，倾向高级别内膜样腺癌&quot;,&quot;laterality&quot;:&quot;Bilateral&quot;,&quot;primary&quot;:&quot;Ovarian malignant tumor&quot;,&quot;site&quot;:&quot;Pelvis / ovary&quot;},&quot;HRD&quot;:&quot;Unknown&quot;,&quot;INITIAL_TREATMENT&quot;:&quot;Yes&quot;,&quot;LINE_OF_THERAPY&quot;:[{&quot;cycles&quot;:&quot;2&quot;,&quot;end_date&quot;:&quot;2025-07-17&quot;,&quot;intent&quot;:&quot;Unknown&quot;,&quot;line&quot;:&quot;1L&quot;,&quot;regimen&quot;:&quot;紫杉醇+卡铂&quot;,&quot;start_date&quot;:&quot;2025-06-24&quot;}],&quot;MAINTENANCE&quot;:&quot;Unknown&quot;,&quot;MAINTENANCE_DETAIL&quot;:{&quot;end_date&quot;:&quot;Unknown&quot;,&quot;given&quot;:&quot;Unknown&quot;,&quot;regimens&quot;:[],&quot;start_date&quot;:&quot;Unknown&quot;},&quot;NEOADJUVANT&quot;:&quot;Unknown&quot;,&quot;PFI_days&quot;:&quot;Unknown&quot;,&quot;PLATINUM_HISTORY&quot;:[{&quot;PFI_days&quot;:&quot;Unknown&quot;,&quot;end_date&quot;:&quot;2025-07-17&quot;,&quot;evidence&quot;:&quot;&quot;,&quot;evidence_type&quot;:&quot;Unknown&quot;,&quot;first_relapse_date&quot;:&quot;Unknown&quot;,&quot;line&quot;:&quot;1L&quot;,&quot;start_date&quot;:&quot;2025-06-24&quot;,&quot;status&quot;:&quot;Unknown&quot;}],&quot;PLATINUM_PFI_CURRENT&quot;:&quot;Unknown&quot;,&quot;PLATINUM_STATUS&quot;:&quot;Unknown&quot;,&quot;PLATINUM_STATUS_CURRENT&quot;:&quot;Unknown&quot;,&quot;RELAPSE&quot;:&quot;Unknown&quot;,&quot;RELAPSE_DATE&quot;:{&quot;date&quot;:&quot;Unknown&quot;,&quot;evidence&quot;:&quot;&quot;,&quot;type&quot;:&quot;Unknown&quot;},&quot;STAGE&quot;:{&quot;stage_basis&quot;:&quot;Unknown&quot;,&quot;stage_system&quot;:&quot;Unknown&quot;,&quot;stage_text&quot;:&quot;Unknown&quot;},&quot;SURGERY_DONE&quot;:{&quot;date&quot;:&quot;2025-08-26&quot;,&quot;performed&quot;:&quot;Yes&quot;,&quot;procedure&quot;:&quot;Radical gastrectomy + total hysterectomy with bilateral adnexectomy + omentectomy + appendectomy + pelvic peritonectomy (abdominal)&quot;},&quot;VISIT_DATE&quot;:&quot;2025-09-22&quot;,&quot;first_relapse_date&quot;:&quot;Unknown&quot;,&quot;last_platinum_end_date&quot;:&quot;2025-07-17&quot;},&quot;LAB_TRENDS&quot;:{&quot;labs&quot;:[{&quot;analyte&quot;:&quot;CA125&quot;,&quot;history&quot;:[{&quot;date&quot;:&quot;2025-07-13&quot;,&quot;flag&quot;:&quot;↑&quot;,&quot;value&quot;:&quot;68&quot;}],&quot;latest&quot;:{&quot;date&quot;:&quot;2025-07-13&quot;,&quot;flag&quot;:&quot;↑&quot;,&quot;value&quot;:&quot;68&quot;},&quot;reference_range&quot;:&quot;Unknown&quot;,&quot;unit&quot;:&quot;U/mL&quot;},{&quot;analyte&quot;:&quot;Hb&quot;,&quot;history&quot;:[{&quot;date&quot;:&quot;2025-07-13&quot;,&quot;flag&quot;:&quot;↓&quot;,&quot;value&quot;:&quot;103&quot;},{&quot;date&quot;:&quot;2025-08-04&quot;,&quot;flag&quot;:&quot;↓&quot;,&quot;value&quot;:&quot;102&quot;}],&quot;latest&quot;:{&quot;date&quot;:&quot;2025-08-04&quot;,&quot;flag&quot;:&quot;↓&quot;,&quot;value&quot;:&quot;102&quot;},&quot;reference_range&quot;:&quot;Unknown&quot;,&quot;unit&quot;:&quot;g/L&quot;},{&quot;analyte&quot;:&quot;Other&quot;,&quot;history&quot;:[{&quot;date&quot;:&quot;2025-07-13&quot;,&quot;flag&quot;:&quot;↓&quot;,&quot;value&quot;:&quot;WBC 3.17&quot;},{&quot;date&quot;:&quot;2025-08-04&quot;,&quot;flag&quot;:&quot;↓&quot;,&quot;value&quot;:&quot;WBC 2.31&quot;}],&quot;latest&quot;:{&quot;date&quot;:&quot;2025-08-04&quot;,&quot;flag&quot;:&quot;↓&quot;,&quot;value&quot;:&quot;WBC 2.31&quot;},&quot;reference_range&quot;:&quot;Unknown&quot;,&quot;unit&quot;:&quot;10^9/L&quot;},{&quot;analyte&quot;:&quot;Other&quot;,&quot;history&quot;:[{&quot;date&quot;:&quot;2025-07-13&quot;,&quot;flag&quot;:&quot;Unknown&quot;,&quot;value&quot;:&quot;Platelets 222&quot;},{&quot;date&quot;:&quot;2025-08-04&quot;,&quot;flag&quot;:&quot;↓&quot;,&quot;value&quot;:&quot;Platelets 124&quot;}],&quot;latest&quot;:{&quot;date&quot;:&quot;2025-08-04&quot;,&quot;flag&quot;:&quot;↓&quot;,&quot;value&quot;:&quot;Platelets 124&quot;},&quot;reference_range&quot;:&quot;Unknown&quot;,&quot;unit&quot;:&quot;10^9/L&quot;}],&quot;milestones&quot;:[{&quot;date&quot;:&quot;2025-06-24&quot;,&quot;description&quot;:&quot;First cycle paclitaxel + carboplatin&quot;,&quot;type&quot;:&quot;ChemoStart&quot;},{&quot;date&quot;:&quot;2025-07-17&quot;,&quot;description&quot;:&quot;Second cycle paclitaxel + carboplatin administered (last documented)&quot;,&quot;type&quot;:&quot;ChemoEnd&quot;},{&quot;date&quot;:&quot;2025-08-26&quot;,&quot;description&quot;:&quot;Radical gastrectomy + hysterectomy + bilateral adnexectomy + omentectomy + appendectomy + pelvic peritonectomy&quot;,&quot;type&quot;:&quot;Surgery&quot;}]},&quot;MED_ONC&quot;:{&quot;current_regimen&quot;:{&quot;cycle_info&quot;:&quot;Unknown&quot;,&quot;last_admin_date&quot;:&quot;Unknown&quot;,&quot;name&quot;:&quot;Unknown&quot;},&quot;genetic_testing&quot;:{&quot;germline&quot;:[],&quot;somatic&quot;:[]},&quot;monitoring_points&quot;:[],&quot;planned_next_regimen&quot;:&quot;Unknown&quot;,&quot;prior_systemic_therapies&quot;:[&quot;紫杉醇+卡铂&quot;]},&quot;NUC_MED&quot;:{&quot;studies&quot;:[{&quot;avid_lesions&quot;:[&quot;bilateral adnexal masses&quot;,&quot;liver lesions&quot;,&quot;hepatic subcapsular lesions&quot;,&quot;cardiophrenic angle lesion&quot;,&quot;porta hepatis nodes&quot;,&quot;retroperitoneal lymph nodes&quot;,&quot;peritoneal and omental lesions&quot;],&quot;confidence&quot;:&quot;Moderate&quot;,&quot;date&quot;:&quot;2025-05-27&quot;,&quot;non_avid_notes&quot;:[],&quot;type&quot;:&quot;FDG-PET/CT&quot;}]},&quot;PATHOLOGY&quot;:{&quot;specimens&quot;:[{&quot;components&quot;:[&quot;gastric mucosa biopsy&quot;],&quot;date&quot;:&quot;2025-06-07&quot;,&quot;diagnosis&quot;:&quot;Low-differentiated adenocarcinoma (loss of adhesion)&quot;,&quot;grade&quot;:&quot;Low-differentiated&quot;,&quot;ihc&quot;:[{&quot;marker&quot;:&quot;MLH1&quot;,&quot;result&quot;:&quot;(+)&quot;},{&quot;marker&quot;:&quot;MSH6&quot;,&quot;result&quot;:&quot;(+)&quot;},{&quot;marker&quot;:&quot;MSH2&quot;,&quot;result&quot;:&quot;(+)&quot;},{&quot;marker&quot;:&quot;PMS2&quot;,&quot;result&quot;:&quot;(+)&quot;},{&quot;marker&quot;:&quot;PAX8&quot;,&quot;result&quot;:&quot;(-)&quot;},{&quot;marker&quot;:&quot;ER&quot;,&quot;result&quot;:&quot;(-)&quot;},{&quot;marker&quot;:&quot;PR&quot;,&quot;result&quot;:&quot;(-)&quot;},{&quot;marker&quot;:&quot;WT1&quot;,&quot;result&quot;:&quot;(-)&quot;},{&quot;marker&quot;:&quot;Claudin 18 (43-14A)&quot;,&quot;result&quot;:&quot;≥75%;2/3+&quot;}],&quot;involvement_sites&quot;:[],&quot;laterality&quot;:&quot;Unknown&quot;,&quot;molecular&quot;:[],&quot;raw_text&quot;:&quot;Gastric antrum biopsy pathology: low-differentiated adenocarcinoma (loss of adhesion). IHC from original unit: MLH1(ES05)(+), MSH6(+), MSH2(+), PMS2(+). Supplementary: combined IHC favors gastric primary adenocarcinoma.&quot;,&quot;sample_type&quot;:&quot;Biopsy&quot;,&quot;site&quot;:&quot;gastric antrum (biopsy)&quot;,&quot;tumor_size&quot;:&quot;Unknown&quot;,&quot;uncertainty_or_missing&quot;:[&quot;Further diagnostic correlation with IHC&quot;]},{&quot;components&quot;:[&quot;peritoneal tumor&quot;,&quot;omental tumor&quot;],&quot;date&quot;:&quot;2025-06-18&quot;,&quot;diagnosis&quot;:&quot;Adenocarcinoma; combined IHC favors female genital tract origin, favors high-grade endometrioid adenocarcinoma&quot;,&quot;grade&quot;:&quot;High-grade&quot;,&quot;ihc&quot;:[{&quot;marker&quot;:&quot;ER&quot;,&quot;result&quot;:&quot;(+)&quot;},{&quot;marker&quot;:&quot;PR&quot;,&quot;result&quot;:&quot;(-)&quot;},{&quot;marker&quot;:&quot;P53&quot;,&quot;result&quot;:&quot;部分+&quot;},{&quot;marker&quot;:&quot;WT1&quot;,&quot;result&quot;:&quot;(+)&quot;},{&quot;marker&quot;:&quot;HNF1B&quot;,&quot;result&quot;:&quot;(-)&quot;},{&quot;marker&quot;:&quot;NapsinA&quot;,&quot;result&quot;:&quot;(-)&quot;},{&quot;marker&quot;:&quot;P16&quot;,&quot;result&quot;:&quot;强+&quot;},{&quot;marker&quot;:&quot;PAX8&quot;,&quot;result&quot;:&quot;(+)&quot;},{&quot;marker&quot;:&quot;CDX-2&quot;,&quot;result&quot;:&quot;(-)&quot;},{&quot;marker&quot;:&quot;CK7&quot;,&quot;result&quot;:&quot;(+)&quot;},{&quot;marker&quot;:&quot;CK20&quot;,&quot;result&quot;:&quot;(-)&quot;}],&quot;involvement_sites&quot;:[&quot;peritoneum&quot;,&quot;omentum&quot;],&quot;laterality&quot;:&quot;Unknown&quot;,&quot;molecular&quot;:[],&quot;raw_text&quot;:&quot;Peritoneal and omental tumor pathology (2025-06-18): adenocarcinoma. Combined with IHC, consider female genital tract origin, favors high-grade endometrioid adenocarcinoma. IHC: ER(+), PR(-), P53(部分+), WT1(+), HNF1B(-), NapsinA(-), P16(强+), PAX8(+), CDX-2(-), SATB2(-), CK7(+), CK20(-).&quot;,&quot;sample_type&quot;:&quot;Biopsy&quot;,&quot;site&quot;:&quot;peritoneum and omentum (biopsy)&quot;,&quot;tumor_size&quot;:&quot;Unknown&quot;,&quot;uncertainty_or_missing&quot;:[&quot;Further IHC confirmation performed&quot;]},{&quot;components&quot;:[&quot;uterus&quot;,&quot;bilateral adnexa&quot;,&quot;pelvic peritoneum&quot;,&quot;hepatic ligament&quot;,&quot;distal stomach&quot;,&quot;omentum&quot;,&quot;appendix&quot;],&quot;date&quot;:&quot;2025-08-26&quot;,&quot;diagnosis&quot;:&quot;High-grade adenocarcinoma involving adnexa and pelvic peritoneum; distal stomach: low-differentiated adenocarcinoma&quot;,&quot;grade&quot;:&quot;High-grade&quot;,&quot;ihc&quot;:[{&quot;marker&quot;:&quot;HER2&quot;,&quot;result&quot;:&quot;0&quot;},{&quot;marker&quot;:&quot;EBER&quot;,&quot;result&quot;:&quot;(-)&quot;},{&quot;marker&quot;:&quot;MLH1(ES05)&quot;,&quot;result&quot;:&quot;(+)&quot;},{&quot;marker&quot;:&quot;MSH2&quot;,&quot;result&quot;:&quot;(+)&quot;},{&quot;marker&quot;:&quot;MSH6&quot;,&quot;result&quot;:&quot;(+)&quot;},{&quot;marker&quot;:&quot;PMS2&quot;,&quot;result&quot;:&quot;(+)&quot;},{&quot;marker&quot;:&quot;CDX-2&quot;,&quot;result&quot;:&quot;(+)&quot;},{&quot;marker&quot;:&quot;CK20&quot;,&quot;result&quot;:&quot;(+)&quot;},{&quot;marker&quot;:&quot;CK7&quot;,&quot;result&quot;:&quot;(+)&quot;},{&quot;marker&quot;:&quot;PAX8&quot;,&quot;result&quot;:&quot;(+)&quot;},{&quot;marker&quot;:&quot;ER&quot;,&quot;result&quot;:&quot;部分+ / (+20% reported)&quot;},{&quot;marker&quot;:&quot;PR&quot;,&quot;result&quot;:&quot;个别+ / (- in some reports)&quot;},{&quot;marker&quot;:&quot;P53&quot;,&quot;result&quot;:&quot;部分+&quot;},{&quot;marker&quot;:&quot;WT1&quot;,&quot;result&quot;:&quot;(+)&quot;},{&quot;marker&quot;:&quot;Ki-67&quot;,&quot;result&quot;:&quot;+20% (report) / +60% (distal stomach)&quot;},{&quot;marker&quot;:&quot;HNF1B&quot;,&quot;result&quot;:&quot;(-)&quot;},{&quot;marker&quot;:&quot;NapsinA&quot;,&quot;result&quot;:&quot;(-)&quot;},{&quot;marker&quot;:&quot;P16&quot;,&quot;result&quot;:&quot;弥漫+&quot;},{&quot;marker&quot;:&quot;IMP3&quot;,&quot;result&quot;:&quot;(+)&quot;},{&quot;marker&quot;:&quot;TTF-1&quot;,&quot;result&quot;:&quot;(-)&quot;},{&quot;marker&quot;:&quot;GATA3&quot;,&quot;result&quot;:&quot;(-)&quot;}],&quot;involvement_sites&quot;:[&quot;left fallopian tube: tumor present&quot;,&quot;right fallopian tube: tumor present&quot;,&quot;uterine endometrium: atrophic&quot;,&quot;pelvic peritoneum: tumor present&quot;,&quot;omentum: tumor present&quot;,&quot;lymph nodes: metastasis 3/25&quot;],&quot;laterality&quot;:&quot;Bilateral&quot;,&quot;molecular&quot;:[],&quot;raw_text&quot;:&quot;Surgical specimen (2025-08-26) pathology: specimens: uterus+bilateral adnexa+pelvic peritoneum+hepatic ligament+distal stomach+omentum+appendix. Bilateral adnexal tumors: left 4.8×3.5×2.5 cm; right 3.5×1.5×0.7 cm. Pathology: high-grade adenocarcinoma; distal stomach: low-differentiated adenocarcinoma 2×1.5×1.5 cm invading submucosa (SM1). Lymph nodes 3/25 positive. IHC summarized in report(s) with PAX8(+), ER(partial+), WT1(+), HER2(0), MMR proteins intact. Diagnostic comment: high-grade adenocarcinoma with therapy-related changes; need to consider high-grade endometrioid vs high-grade serous; molecular testing may be added.&quot;,&quot;sample_type&quot;:&quot;Surgical resection&quot;,&quot;site&quot;:&quot;whole surgical specimen: uterus + bilateral adnexa + pelvic peritoneum + hepatic ligament + distal stomach + omentum + appendix&quot;,&quot;tumor_size&quot;:&quot;Left:4.8×3.5×2.5 cm; Right:3.5×1.5×0.7 cm; distal stomach tumor 2×1.5×1.5 cm&quot;,&quot;uncertainty_or_missing&quot;:[&quot;Distinction between high-grade endometrioid and high-grade serous not definitive; molecular testing suggested&quot;]}]},&quot;RADIOLOGY&quot;:{&quot;next_imaging_plan&quot;:{&quot;modality&quot;:&quot;Unknown&quot;,&quot;timing&quot;:&quot;Unknown&quot;},&quot;studies&quot;:[{&quot;anatomic_sites&quot;:[&quot;bilateral adnexa&quot;,&quot;liver&quot;,&quot;hepatic subcapsular&quot;,&quot;cardiophrenic angle&quot;,&quot;porta hepatis&quot;,&quot;retroperitoneal lymph nodes&quot;,&quot;peritoneum&quot;,&quot;omentum&quot;,&quot;ascites&quot;],&quot;date&quot;:&quot;2025-05-27&quot;,&quot;findings&quot;:[&quot;Bilateral adnexal masses suspicious for ovarian cancer&quot;,&quot;Metastases to liver, hepatic subcapsular area, cardiophrenic angle, porta hepatis, retroperitoneal nodes&quot;,&quot;Peritoneal and omental metastases&quot;,&quot;Abdominal and pelvic ascites&quot;],&quot;impression&quot;:&quot;Bilateral adnexal masses suspicious for ovarian cancer with multifocal metastatic disease including liver, nodes, peritoneum, omentum; ascites&quot;,&quot;modality&quot;:&quot;Other&quot;,&quot;trend_vs_prior&quot;:&quot;Unknown&quot;}]},&quot;TIMELINE&quot;:{&quot;constraints&quot;:{&quot;max_events&quot;:30,&quot;min_events&quot;:3,&quot;must_include&quot;:[&quot;first diagnostic imaging or pathology confirmation (if available)&quot;],&quot;ordering_rules&quot;:{&quot;prioritize_last_event&quot;:true}},&quot;events&quot;:[{&quot;date&quot;:&quot;2025-05-27&quot;,&quot;description&quot;:&quot;FDG-PET/CT showing bilateral adnexal masses and widespread metastases&quot;,&quot;event_type&quot;:&quot;Imaging&quot;,&quot;key_result&quot;:&quot;Bilateral adnexal masses; liver, hepatic subcapsular, cardiophrenic angle, porta hepatis, retroperitoneal nodes, peritoneal and omental metastases; ascites&quot;,&quot;regimen_or_test&quot;:&quot;PET/CT&quot;},{&quot;date&quot;:&quot;2025-06-05&quot;,&quot;description&quot;:&quot;Laparoscopic exploration and pelvic mass biopsy and omental biopsy&quot;,&quot;event_type&quot;:&quot;Surgery&quot;,&quot;key_result&quot;:&quot;Biopsies obtained for pathology&quot;,&quot;regimen_or_test&quot;:&quot;Laparoscopy with biopsies&quot;},{&quot;date&quot;:&quot;2025-06-07&quot;,&quot;description&quot;:&quot;Gastric biopsy pathology&quot;,&quot;event_type&quot;:&quot;Other&quot;,&quot;key_result&quot;:&quot;Low-differentiated adenocarcinoma (loss of adhesion)&quot;,&quot;regimen_or_test&quot;:&quot;Gastroscopy biopsy&quot;},{&quot;date&quot;:&quot;2025-06-18&quot;,&quot;description&quot;:&quot;Peritoneal and omental tumor pathology&quot;,&quot;event_type&quot;:&quot;Pathology&quot;,&quot;key_result&quot;:&quot;Adenocarcinoma; combined IHC favors female genital tract origin, favors high-grade endometrioid adenocarcinoma&quot;,&quot;regimen_or_test&quot;:&quot;Pathology with IHC&quot;},{&quot;date&quot;:&quot;2025-06-24&quot;,&quot;description&quot;:&quot;First cycle paclitaxel + carboplatin&quot;,&quot;event_type&quot;:&quot;Chemo&quot;,&quot;key_result&quot;:&quot;Cycle 1 administered&quot;,&quot;regimen_or_test&quot;:&quot;紫杉醇+卡铂&quot;},{&quot;date&quot;:&quot;2025-07-13&quot;,&quot;description&quot;:&quot;Outside lab tests&quot;,&quot;event_type&quot;:&quot;Lab&quot;,&quot;key_result&quot;:&quot;WBC 3.17↓; Hb 103↓; Platelets 222; CA125 68↑&quot;,&quot;regimen_or_test&quot;:&quot;CBC and tumor markers&quot;},{&quot;date&quot;:&quot;2025-07-17&quot;,&quot;description&quot;:&quot;Second cycle paclitaxel + carboplatin&quot;,&quot;event_type&quot;:&quot;Chemo&quot;,&quot;key_result&quot;:&quot;Cycle 2 administered&quot;,&quot;regimen_or_test&quot;:&quot;紫杉醇+卡铂&quot;},{&quot;date&quot;:&quot;2025-08-04&quot;,&quot;description&quot;:&quot;Outside CBC&quot;,&quot;event_type&quot;:&quot;Lab&quot;,&quot;key_result&quot;:&quot;WBC 2.31↓; Hb 102↓; Platelets 124&quot;,&quot;regimen_or_test&quot;:&quot;CBC&quot;},{&quot;date&quot;:&quot;2025-08-26&quot;,&quot;description&quot;:&quot;Radical gastrectomy + total hysterectomy with bilateral adnexectomy + omentectomy + appendectomy + pelvic peritonectomy&quot;,&quot;event_type&quot;:&quot;Surgery&quot;,&quot;key_result&quot;:&quot;Resection performed; multiple specimens sent&quot;,&quot;regimen_or_test&quot;:&quot;Abdominal surgery&quot;},{&quot;date&quot;:&quot;2025-09-01&quot;,&quot;description&quot;:&quot;Surgical specimen pathology reports&quot;,&quot;event_type&quot;:&quot;Pathology&quot;,&quot;key_result&quot;:&quot;High-grade adenocarcinoma involving adnexa and pelvic peritoneum; distal stomach low-differentiated adenocarcinoma; lymph node metastases (3/25)&quot;,&quot;regimen_or_test&quot;:&quot;Surgical pathology with IHC&quot;},{&quot;date&quot;:&quot;2025-09-22&quot;,&quot;description&quot;:&quot;Postoperative review visit&quot;,&quot;event_type&quot;:&quot;Other&quot;,&quot;key_result&quot;:&quot;Postoperative follow-up&quot;,&quot;regimen_or_test&quot;:&quot;Clinic visit&quot;}]}}</pre>
      </details>
    </div>
  </div>

  <details class="mt" open>
    <summary>Expert Debate (Round × Turn)</summary>
    <table class='grid'><tr><th>Round</th><th>Turn</th><th>From</th><th>To</th><th>Message</th></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 1</td><td class='mono'>oncologist</td><td class='mono'>chair</td><td>Systemic regimen choice is currently guesswork because we still lack final surgical pathology (both primaries), formal staging, and post‑operative imaging to define which tumour is driving residual peritoneal disease; these must be available before agreeing on systemic strategy.</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 1</td><td class='mono'>oncologist</td><td class='mono'>radiologist</td><td>Please confirm timing and protocol for post‑operative contrast CT (and whether PET/CT adds value) to characterize residual peritoneal, nodal, liver, adrenal, and lung disease before systemic therapy recommencement.</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 1</td><td class='mono'>oncologist</td><td class='mono'>pathologist</td><td>We urgently need integrated final reports for gastric and Müllerian primaries, including FIGO/TNM stage, residual disease assessment, and a clear opinion on which tumour most likely accounts for the peritoneal/upper‑abdominal deposits, to guide systemic regimen selection.</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 1</td><td class='mono'>oncologist</td><td class='mono'>nuclear</td><td>Given baseline FDG‑avid peritoneal and nodal disease, advise whether repeat PET/CT now would meaningfully refine attribution between gastric versus Müllerian primary and alter systemic treatment planning.</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 1</td><td class='mono'>radiologist</td><td class='mono'>oncologist</td><td>No post‑operative imaging is available; updated contrast-enhanced CT (chest/abdomen/pelvis) or PET/CT is needed now to define residual metastatic burden and complications.</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 1</td><td class='mono'>radiologist</td><td class='mono'>nuclear</td><td>If PET/CT is being considered, please plan whole-body FDG-PET/CT for restaging to clarify dominant primary source of current peritoneal/upper-abdominal disease.</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 1</td><td class='mono'>pathologist</td><td class='mono'>chair</td><td>Final synoptic surgical pathology for both Müllerian and gastric primaries (including FIGO/TNM staging and residual disease status) is missing and essential to attribute current disease burden and guide systemic planning.</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 1</td><td class='mono'>pathologist</td><td class='mono'>oncologist</td><td>Pathology strongly favors Müllerian high‑grade serous adenocarcinoma as the source of diffuse peritoneal/omental disease; please confirm that systemic strategy is being based primarily on the Müllerian biology rather than gastric histology alone.</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 1</td><td class='mono'>nuclear</td><td class='mono'>oncologist</td><td>Given dual primaries and complex peritoneal involvement, a post‑operative FDG‑PET/CT would better clarify dominant primary and residual metabolic disease than CT alone for current restaging.</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 1</td><td class='mono'>nuclear</td><td class='mono'>radiologist</td><td>Please comment whether prior FDG‑avid cardiophrenic and porta hepatis nodes and hepatic capsular lesions were fully evaluated or seen on August CT, as this impacts the value of repeat PET/CT now.</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 2</td><td class='mono'>oncologist</td><td class='mono'>chair</td><td>Systemic planning must now prioritize the Müllerian high‑grade serous biology as the main driver of peritoneal disease, but we still lack complete gastric and Müllerian staging, residual disease description, and formal operative notes, which are critical before finalizing regimen and sequencing between the two primaries.</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 2</td><td class='mono'>oncologist</td><td class='mono'>radiologist</td><td>In light of nuclear medicine’s view that repeat PET/CT may better define dominant primary and residual metabolic disease, please advise how this would complement or alter contrast CT‑based restaging and whether prior cardiophrenic/porta hepatis and hepatic capsular lesions were adequately characterized on the August CT.</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 2</td><td class='mono'>oncologist</td><td class='mono'>pathologist</td><td>We accept Müllerian high‑grade serous carcinoma as the dominant source of peritoneal/omental disease; please expedite full synoptic reports with FIGO/TNM staging and explicit residual disease assessment for both primaries to finalize systemic intent and prioritization.</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 2</td><td class='mono'>oncologist</td><td class='mono'>nuclear</td><td>Your recommendation for post‑operative PET/CT is noted; we need a concise protocol and reporting focus (dominant primary attribution, cardiophrenic/porta hepatis/hepatic capsular and adrenal assessment) to ensure it directly influences systemic regimen choice.</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 2</td><td class='mono'>radiologist</td><td class='mono'>nuclear</td><td>August CT reports only describe upper-abdominal/perihepatic peritoneal thickening and mildly enlarged nodes; prior FDG-avid cardiophrenic and porta hepatis nodes and hepatic capsular lesions were not individually characterized, so repeat PET/CT would add value for metabolic restaging and nodal/liver assessment.</td></tr><tr><td class='mono'>Round 2</td><td class='mono'>Turn 1</td><td class='mono'>pathologist</td><td class='mono'>oncologist</td><td>Please ensure final synoptic pathology is obtained; without FIGO/TNM staging and residual disease status, dominant primary attribution remains insufficiently documented for systemic planning.</td></tr></table>
    <div class="hint">Only includes messages that were actually emitted (non-empty).</div>
  </details>

  <details class="mt">
    <summary>Initial Expert Opinions (raw)</summary>
    <pre>{
  &quot;chair&quot;: &quot;- Clarify primary: integrate gastric vs Müllerian origin with pathology, consider additional molecular tests; this drives systemic treatment strategy.  \n\n- Stage post-surgery with contrast CT/PET and operative notes to define residual disease burden; current postoperative imaging status unknown/needs update.  \n\n- Plan to resume systemic therapy soon after recovery, coordinated between gastric and gynecologic oncology, given prior brief platinum exposure.  \n\n- Arrange germline and somatic testing (including BRCA/HRD, others) to inform maintenance and future-line options; currently unknown/needs update.  \n\n- Monitor recovery: repeat CA125, nutritional status, and anemia workup; ensure no infection or complications given postoperative leukocytosis and low Hb.&quot;,
  &quot;oncologist&quot;: &quot;- High-grade endometrioid-like ovarian carcinoma with extensive peritoneal and gastric involvement → systemic therapy intent is adjuvant/primary postoperative, not surveillance.\n\n- Only two cycles of first-line platinum-taxane documented pre-op; decision now: resume systemic chemotherapy vs switch strategy based on pathology/staging.\n\n- Current organ function acceptable for cytotoxic therapy: normal liver/renal biochemistry [@20250907|10100012]; marrow recovered (WBC/PLT adequate, mild anemia) [@20250923|5601694].\n\n- CA125 normalized post-chemotherapy/surgery (68→20.9 U/mL) [@20250818|9701134], but imaging status and residual disease burden are unknown/needs update.\n\n- Missing critical data: final surgical pathology stage, residual disease description, detailed histologic report, germline/somatic HRD-BRCA testing, and current ECOG status.&quot;,
  &quot;radiologist&quot;: &quot;- Bilateral adnexal cystic–solid masses ~49×48 mm with enhancing solid components, compatible with residual/recurrent ovarian malignancy [@2025-08-15|CT].\n\n- Peritoneal/omental thickening and nodularity along hepatic capsule and abdomen, consistent with peritoneal carcinomatosis; no ascites currently seen [@2025-08-15|CT].\n\n- Mildly enlarged lymph nodes at cardiophrenic/anterior diaphragmatic, porta hepatis, and retroperitoneal regions, suspicious for nodal metastases [@2025-08-15|CT; @2025-08-19|CT].\n\n- Tiny right upper lobe pulmonary nodule (3 mm); indeterminate, recommend interval CT chest surveillance [@2025-08-19|CT].\n\n- Left adrenal gland mildly thickened without discrete mass; metastatic involvement indeterminate, needs interval imaging correlation [@2025-08-15|CT].&quot;,
  &quot;pathologist&quot;: &quot;- There are two primaries: gastric poorly differentiated adenocarcinoma and high‑grade Müllerian adenocarcinoma involving adnexa/peritoneum.  \n\n- Müllerian tumor profile (PAX8+, WT1+, ER partial+, p16 diffuse, MMR intact) favors high‑grade serous over endometrioid.  \n\n- Distal gastric tumor: poorly differentiated adenocarcinoma with CDX2+/CK20+/Claudin18+, HER2 0, MMR intact; appears separate primary.  \n\n- FIGO stage for Müllerian carcinoma and pathologic stage for gastric cancer cannot be assigned from current reports; staging details needed.  \n\n- Recommended updates: full synoptic surgical report, confirm primary site assignment, and add molecular panel (e.g., TP53, BRCA/HRR) for Müllerian tumor.&quot;,
  &quot;nuclear&quot;: &quot;- FDG-avid bilateral adnexal masses with multifocal liver, nodal, peritoneal, omental disease indicate advanced-stage ovarian malignancy at baseline staging. [@FDG-PET/CT|2025-05-27]\n\n- PET significantly upstaged disease by revealing hepatic, porta hepatis, cardiophrenic, and extensive peritoneal/omental involvement beyond pelvis. [@FDG-PET/CT|2025-05-27]\n\n- Interval CT shows persistent bilateral adnexal masses and peritoneal/omental nodularity, consistent with residual/metastatic disease after surgery/chemotherapy. [@2025-08-15|CT]\n\n- Cardiophrenic and upper-abdominal nodal disease on PET support systemic dissemination; these nodes are difficult to fully characterize on CT alone. [@FDG-PET/CT|2025-05-27; @2025-08-19|CT]\n\n- For current restaging/recurrence assessment, updated FDG-PET/CT after August CT is needed to reassess metabolic response and residual disease.&quot;
}</pre>
  </details>

  <details class="mt">
    <summary>Final Refined Plans (per round, raw)</summary>
    <pre>{
  &quot;Round 1&quot;: {
    &quot;chair&quot;: &quot;- Confirm staging, residual disease status and current CA125 via updated contrast CT/PET-CT and tumor markers before adjuvant planning (currently unknown).  \n- Coordinate medical oncology to resume systemic therapy with platinum-based backbone given high-grade Müllerian carcinoma and prior partial neoadjuvant exposure [@2025-08-26|2025-08-26].  \n- Request germline and somatic genomic testing including BRCA/HRR, HRD and PDL1/TMB to guide maintenance and future options (currently unknown).  \n- Monitor postoperative recovery, cytopenia resolution, and organ function with repeat CBC and CMP before restarting chemotherapy [@20250902|2025-09-02].  \n- Establish surveillance plan: interval imaging, CA125, and symptom review; define triggers for restaging or change of systemic strategy (currently unknown).&quot;,
    &quot;oncologist&quot;: &quot;- Prior systemic therapy limited to two platinum‑taxane cycles; further combination chemotherapy is feasible, pending staging and performance status confirmation (ECOG unknown).  \n\n- Hematologic recovery and organ function currently adequate for cytotoxic therapy; anemia mild (Hgb 96 g/L [@20250923|5601694], chemistries acceptable [@20250907|10100012]).  \n\n- Tumor burden and regimen choice should prioritize Müllerian high‑grade serous biology as dominant driver of peritoneal disease; gastric burden requires formal staging (pathology, operative notes pending).  \n\n- Obtain comprehensive synoptic pathology for both primaries with FIGO/TNM staging and residual disease description, plus updated contrast CT and FDG‑PET/CT for post‑operative restaging.  \n\n- Initiate germline and somatic profiling (BRCA/HRD/HRR and broader panel) for Müllerian tumor; expand gastric molecular workup beyond HER2/MMR (currently HER2 0, MMR intact—dates unknown).&quot;,
    &quot;radiologist&quot;: &quot;- Obtain post‑operative contrast CT chest/abdomen/pelvis to document residual peritoneal, nodal, hepatic capsular, adrenal and pulmonary disease [@2025-08-15|CT; @2025-08-19|CT].  \n\n- Perform whole‑body FDG‑PET/CT to reassess cardiophrenic, porta hepatis, hepatic capsular, retroperitoneal nodes and adrenal, and clarify dominant primary [@2025-05-27|FDG-PET/CT].  \n\n- Use PET/CT plus CT to generate measurable target/non‑target lesions for ongoing response assessment (peritoneum/omentum, adnexal, nodal, hepatic capsular, lung) [@2025-08-15|CT; @2025-08-19|CT].  \n\n- Correlate new imaging with final surgical pathology to attribute peritoneal/upper‑abdominal disease to Müllerian versus gastric origin (pathology staging currently unknown).  \n\n- Reassess the 3 mm RUL lung nodule and left adrenal thickening on follow‑up CT/PET to distinguish metastasis from benign findings [@2025-08-19|CT; @2025-08-15|CT].&quot;,
    &quot;pathologist&quot;: &quot;- Confirm final synoptic surgical pathology for Müllerian and gastric primaries, including FIGO/TNM staging and residual disease description (currently unknown).  \n\n- Pathologically attribute diffuse peritoneal/omental disease primarily to high‑grade Müllerian carcinoma; gastric component appears a separate, localized SM1 lesion [@HISTOLOGY_AND_IHC.1|2025-06-18,@HISTOLOGY_AND_IHC.2|2025-08-26].  \n\n- Request integrated pathology addendum explicitly stating dominant primary for peritoneal involvement and clarifying high‑grade serous vs endometrioid features (morphology, TP53 if available).  \n\n- Recommend comprehensive molecular profiling of Müllerian tumor (including TP53, BRCA/HRR, broader panel); gastric tumor profiling beyond HER2/MMR remains unknown.  \n\n- After imaging restaging, correlate PET/CT and CT targets with pathology-mapped sites (adnexa, peritoneum, nodes, stomach) to refine disease attribution.&quot;,
    &quot;nuclear&quot;: &quot;- Perform post‑operative whole‑body FDG‑PET/CT for metabolic restaging and dominant primary attribution; compare directly with baseline PET pattern. [@FDG-PET/CT|2025-05-27]  \n\n- Emphasize detailed assessment of cardiophrenic, porta hepatis, retroperitoneal nodes and hepatic capsular/subcapsular lesions versus August CT. [@FDG-PET/CT|2025-05-27; @2025-08-15|CT]  \n\n- Carefully evaluate residual pelvic/adnexal, peritoneal, and omental disease burden and distribution to support Müllerian versus gastric origin attribution. [@FDG-PET/CT|2025-05-27; @2025-08-15|CT]  \n\n- Include focused review of left adrenal morphology/metabolism and right upper‑lobe nodule uptake to refine staging. [@2025-08-15|CT; @2025-08-19|CT]  \n\n- Report should explicitly state whether PET findings would reclassify stage, alter dominant primary assignment, or reveal new metastatic sites. [@FDG-PET/CT|2025-05-27]&quot;
  },
  &quot;Round 2&quot;: {
    &quot;chair&quot;: &quot;- Confirm extent of residual disease with post-operative contrast CT/PET-CT before finalizing systemic strategy; current status unknown.  \n\n- Obtain germline and somatic profiling including BRCA/HRD, MMR/MSI confirmation, and PD-L1/TMB if feasible; all currently unknown.  \n\n- Plan to resume systemic therapy with platinum-based backbone for metastatic high-grade Müllerian-type adnexal carcinoma; coordinate with gastric oncology team.  \n\n- Monitor recovery and cytopenias closely: Hb 96 g/L, WBC 16.9, PLT 212 post-op [@20250923|5601694]; trend CA125 [@20250818|9701134].  \n\n- Clarify staging and primary site dominance integrating pathology and imaging [@2025-08-15|CT; @2025-09-01|Pathology]; document intent (palliative vs maximal disease-control).&quot;,
    &quot;oncologist&quot;: &quot;- Prioritize Müllerian-directed systemic therapy after staging, given extensive Müllerian-pattern peritoneal disease and limited prior platinum exposure (two pre-op cycles).  \n\n- Obtain final synoptic pathology for gastric and Müllerian primaries with FIGO/TNM stage and residual disease status to confirm dominant driver.  \n\n- Restage with contrast CT and consider FDG-PET/CT to characterize cardiophrenic/porta hepatis nodes, hepatic capsular, adrenal, and lung lesions (post-op status unknown).  \n\n- Initiate germline and somatic profiling for Müllerian and gastric tumors (BRCA/HRD/HRR and gastric-specific targets) to inform future maintenance/second-line options.  \n\n- Before restarting systemic therapy, document ECOG, nutrition, anemia evaluation, and postoperative complications; verify current CA125 and organ function (latest CA125 20.9 U/mL [@20250818|9701134], chemistries adequate [@20250907|10100012]).&quot;,
    &quot;radiologist&quot;: &quot;- Restage with contrast-enhanced CT chest/abdomen/pelvis to document current peritoneal/omental, nodal, hepatic capsular, adrenal and pulmonary disease [@2025-08-15|CT; @2025-08-19|CT].  \n\n- Perform post‑operative FDG‑PET/CT to assess residual metabolic disease, especially cardiophrenic, porta hepatis, hepatic capsular, retroperitoneal nodes and adrenal [@2025-05-27|FDG-PET/CT].  \n\n- Correlate CT/PET with full synoptic pathology (FIGO/TNM, residual disease) to support attribution of peritoneal/upper‑abdominal disease to Müllerian origin (pathology staging unknown).  \n\n- On follow‑up CT/PET, re‑evaluate the tiny RUL lung nodule and left adrenal thickening to differentiate metastasis from benign findings [@2025-08-19|CT; @2025-08-15|CT].  \n\n- Use combined CT/PET findings to define measurable target and non‑target lesions for subsequent radiologic response assessment across both primaries [@2025-08-15|CT; @2025-08-19|CT; @2025-05-27|FDG-PET/CT].&quot;,
    &quot;pathologist&quot;: &quot;- Obtain full synoptic reports for gastric and Müllerian primaries with FIGO/TNM stage and residual disease status (currently unknown).  \n\n- Issue integrated pathology addendum explicitly attributing diffuse peritoneal/upper‑abdominal disease to Müllerian carcinoma, not gastric spread [@HISTOLOGY_AND_IHC.1|2025-06-18,@HISTOLOGY_AND_IHC.2|2025-08-26].  \n\n- Restage with contrast CT ± FDG‑PET/CT to map residual metabolically active disease to Müllerian versus gastric origin (imaging post‑August unknown).  \n\n- Initiate comprehensive germline and somatic profiling for Müllerian tumor and extended gastric panel; BRCA/HRR/TP53 status currently unknown.  \n\n- Maintain serial CA125 monitoring and correlate with imaging and pathology‑defined Müllerian disease burden; CA125 20.9 U/mL post‑chemotherapy [@MOLECULAR|2025-07-13].&quot;,
    &quot;nuclear&quot;: &quot;- Recommend post‑operative whole‑body FDG‑PET/CT to reassess metabolic burden and clarify dominant primary pattern versus baseline. [@FDG-PET/CT|2025-05-27]  \n\n- Specifically evaluate cardiophrenic, porta hepatis, and retroperitoneal nodes and hepatic capsular/perihepatic lesions not detailed on August CT. [@FDG-PET/CT|2025-05-27; @2025-08-15|CT]  \n\n- Correlate pelvic/adnexal, peritoneal, and omental uptake distribution with pathology to support Müllerian versus gastric origin attribution. [@FDG-PET/CT|2025-05-27]  \n\n- Assess left adrenal and tiny right‑upper‑lobe nodule metabolism to refine current staging and metastatic spread. [@2025-08-15|CT; @2025-08-19|CT]  \n\n- Explicitly state in the PET report whether findings would upstage, downstage, or reassign dominant primary driving systemic planning. [@FDG-PET/CT|2025-05-27]&quot;
  }
}</pre>
  </details>

  <details class="mt">
    <summary>Selected Clinical Context (JSON)</summary>
    <pre>{
  &quot;lab&quot;: {
    &quot;chair&quot;: [
      {
        &quot;report_id&quot;: &quot;20250818|9701134&quot;,
        &quot;date&quot;: &quot;2025-08-18T00:00:00&quot;,
        &quot;raw_text&quot;: &quot;抗缪勒管激素 &lt;0.01 ng/ml (AMH)\n糖链抗原15-3 10.40 U/ml (CA15-3)\n雌二醇 &lt;37.00 pmol/L (E2)\n神经元特异烯醇化酶 7.80 ng/ml (NSE)\n卵泡刺激素 56.54 IU/L (FSH)\n卵巢恶性肿瘤风险值. 24.52 %(绝经后) (ROMA.)\n糖链抗原125 20.90 U/ml (CA125)\n糖链抗原19-9 12.00 U/ml (CA19-9)\n泌乳素 389.53 mIU/L (PRL)\n黄体生成素 21.43 IU/L (LH)\n孕酮 0.45 nmol/L (PROGEST)\n卵巢恶性肿瘤风险值 27.66 %(绝经前) (ROMA)\n癌胚抗原 2.98 ng/ml (CEA)\n甲胎蛋白 2.04 ng/ml (AFP)\n鳞状细胞癌相关抗原 1.01 ng/ml (SCCA)\n绒毛膜促性腺激素β &lt;1.20 IU/L (HCG-B)\n人附睾蛋白4 95.40 pmol/L (HE4)&quot;
      },
      {
        &quot;report_id&quot;: &quot;20250902|8300228&quot;,
        &quot;date&quot;: &quot;2025-09-02T00:00:00&quot;,
        &quot;raw_text&quot;: &quot;直接胆红素 6.5 umol/l (DBIL)\n钙 2.13 mmol/l (CA)\n葡萄糖 4.88 mmol/l (GLU)\n乳酸脱氢酶 156 U/L (LDH)\n丙氨酸氨基转移酶 13.1 U/l (ALT)\n肌酐 77 umol/l (CRE)\n白球比例 1.48 nan (A/G)\n总蛋白 61.3 g/l (TP)\n球蛋白 24.7 g/l (GELO)\n镁 0.79 mmol/L (MG)\n白蛋白 36.6 g/l (ALB)\n谷草同工酶 5.2 U/L (ASTM)\n游离脂肪酸 1.22 mmol/L (NEFA)\n钠 139.0 mmol/L (NA )\n无机磷 1.09 mmol/L (P)\n碱性磷酸酶 66.1 U/L (ALP)\n前白蛋白 133 mg/L (PA)\n钾 4.26 mmol/L (K)\n间接胆红素 6.5 umol/L (IBIL)\n总胆红素 13.0 umol/l (TBIL)\n谷氨酸脱氢酶 3.4 U/L (GLDH)\n尿素 1.76 mmol/l (UREA)\nγ-谷氨酰基转移酶 25 U/L (GGT)\n总二氧化碳 25.9 mmol/L (TCO2)\n氯 102.0 mmol/L (CL)\n胱抑素C 0.98 mg/L (CYSC)\n尿酸 151 umol/l (UA)\n天冬氨酸氨基转移酶 16.1 U/L (AST)&quot;
      },
      {
        &quot;report_id&quot;: &quot;20250923|5601694&quot;,
        &quot;date&quot;: &quot;2025-09-23T00:00:00&quot;,
        &quot;raw_text&quot;: &quot;血红蛋白量 96 g/l (HGB)\n平均红细胞体积 100.9 fl (MCV)\n自动审核标志 ACCEPT nan (VFLAG)\n白细胞计数 16.9 *10^9/L (WBC)\n平均红细胞血红蛋白浓度 300.0 g/l (MCHC)\n血小板压积 0.19 % (PCT)\nRBC分布宽度-SD 61 nan (RDWSD)\n单核细胞数 0.7 *10^9/L (MID#)\nPLT分布宽度 9 % (PDW)\n嗜碱性细胞数 0.04 *10^9/L (BASO#)\n嗜碱性细胞% 0.20 % (BASO)\n中性粒细胞% 85.6 % (GRAN)\n红细胞比积 32.0 % (HCT)\n平均红细胞血红蛋白量 30.3 pg (MCH)\n淋巴细胞数 1.5 *10^9/L (LYM#)\n中性粒细胞数 14.4 *10^9/L (GRAN#)\n平均PLT容积 9.0 fl (MPV)\n中性淋巴比值 9.60 nan (NL)\n嗜酸性细胞数 0.21 *10^9/L (EOS#)\n嗜酸性细胞% 1.20 % (EOS)\n淋巴细胞% 8.7 % (LYM)\n单核细胞% 4.3 % (MID)\n血小板计数 212 *10^9/L (PLT)\nRBC分布宽度-CV 16.3 % (RDWCV)\n红细胞计数 3.17 *10^12/L (RBC)&quot;
      }
    ],
    &quot;oncologist&quot;: [
      {
        &quot;report_id&quot;: &quot;20250818|9701134&quot;,
        &quot;date&quot;: &quot;2025-08-18T00:00:00&quot;,
        &quot;raw_text&quot;: &quot;抗缪勒管激素 &lt;0.01 ng/ml (AMH)\n糖链抗原15-3 10.40 U/ml (CA15-3)\n雌二醇 &lt;37.00 pmol/L (E2)\n神经元特异烯醇化酶 7.80 ng/ml (NSE)\n卵泡刺激素 56.54 IU/L (FSH)\n卵巢恶性肿瘤风险值. 24.52 %(绝经后) (ROMA.)\n糖链抗原125 20.90 U/ml (CA125)\n糖链抗原19-9 12.00 U/ml (CA19-9)\n泌乳素 389.53 mIU/L (PRL)\n黄体生成素 21.43 IU/L (LH)\n孕酮 0.45 nmol/L (PROGEST)\n卵巢恶性肿瘤风险值 27.66 %(绝经前) (ROMA)\n癌胚抗原 2.98 ng/ml (CEA)\n甲胎蛋白 2.04 ng/ml (AFP)\n鳞状细胞癌相关抗原 1.01 ng/ml (SCCA)\n绒毛膜促性腺激素β &lt;1.20 IU/L (HCG-B)\n人附睾蛋白4 95.40 pmol/L (HE4)&quot;
      },
      {
        &quot;report_id&quot;: &quot;20250907|10100012&quot;,
        &quot;date&quot;: &quot;2025-09-07T00:00:00&quot;,
        &quot;raw_text&quot;: &quot;尿素 1.37 mmol/l (UREA)\nγ-谷氨酰基转移酶 22 U/L (GGT)\n总二氧化碳 26.5 mmol/L (TCO2)\n氯 104.0 mmol/L (CL)\n胱抑素C 1.15 mg/L (CYSC)\n尿酸 342 umol/l (UA)\n天冬氨酸氨基转移酶 14.9 U/L (AST)\n钙 2.22 mmol/l (CA)\n直接胆红素 7.1 umol/l (DBIL)\n自动审核标志 unaccept nan (VFLAG)\n白球比例 1.34 nan (A/G)\n肌酐 67 umol/l (CRE)\n葡萄糖 4.71 mmol/l (GLU)\n乳酸脱氢酶 182 U/L (LDH)\n丙氨酸氨基转移酶 8.0 U/l (ALT)\n钠 141.0 mmol/L (NA )\n无机磷 0.79 mmol/L (P)\n游离脂肪酸 1.00 mmol/L (NEFA)\n谷氨酸脱氢酶 2.7 U/L (GLDH)\n总胆红素 15.4 umol/l (TBIL)\n谷草同工酶 4.3 U/L (ASTM)\n总蛋白 67.1 g/l (TP)\n球蛋白 28.7 g/l (GELO)\n镁 0.81 mmol/L (MG)\n白蛋白 38.4 g/l (ALB)\n钾 4.18 mmol/L (K)\n碱性磷酸酶 59.4 U/L (ALP)\n前白蛋白 120 mg/L (PA)\n间接胆红素 8.3 umol/L (IBIL)&quot;
      },
      {
        &quot;report_id&quot;: &quot;20250923|5601694&quot;,
        &quot;date&quot;: &quot;2025-09-23T00:00:00&quot;,
        &quot;raw_text&quot;: &quot;血红蛋白量 96 g/l (HGB)\n平均红细胞体积 100.9 fl (MCV)\n自动审核标志 ACCEPT nan (VFLAG)\n白细胞计数 16.9 *10^9/L (WBC)\n平均红细胞血红蛋白浓度 300.0 g/l (MCHC)\n血小板压积 0.19 % (PCT)\nRBC分布宽度-SD 61 nan (RDWSD)\n单核细胞数 0.7 *10^9/L (MID#)\nPLT分布宽度 9 % (PDW)\n嗜碱性细胞数 0.04 *10^9/L (BASO#)\n嗜碱性细胞% 0.20 % (BASO)\n中性粒细胞% 85.6 % (GRAN)\n红细胞比积 32.0 % (HCT)\n平均红细胞血红蛋白量 30.3 pg (MCH)\n淋巴细胞数 1.5 *10^9/L (LYM#)\n中性粒细胞数 14.4 *10^9/L (GRAN#)\n平均PLT容积 9.0 fl (MPV)\n中性淋巴比值 9.60 nan (NL)\n嗜酸性细胞数 0.21 *10^9/L (EOS#)\n嗜酸性细胞% 1.20 % (EOS)\n淋巴细胞% 8.7 % (LYM)\n单核细胞% 4.3 % (MID)\n血小板计数 212 *10^9/L (PLT)\nRBC分布宽度-CV 16.3 % (RDWCV)\n红细胞计数 3.17 *10^12/L (RBC)&quot;
      }
    ],
    &quot;radiologist&quot;: [],
    &quot;pathologist&quot;: [],
    &quot;nuclear&quot;: []
  },
  &quot;imaging&quot;: {
    &quot;chair&quot;: [
      {
        &quot;report_id&quot;: &quot;2025-06-04|CT&quot;,
        &quot;date&quot;: &quot;2025-06-04T17:10:08&quot;,
        &quot;raw_text&quot;: &quot;CTA造影可见两侧肺动脉主干及其近端分支形态光整，未见明显充盈缺损或狭窄，两肺动脉远端分支充盈欠佳。横膈前组多发淋巴结肿大。 两肺动脉远端分支充盈欠佳；两肺动脉主干及其近端分支未见明显异常，请结合临床及随访。 横膈前组多发淋巴结肿大。&quot;
      },
      {
        &quot;report_id&quot;: &quot;2025-08-15|CT&quot;,
        &quot;date&quot;: &quot;2025-08-15T17:25:01&quot;,
        &quot;raw_text&quot;: &quot;肝包膜、网膜、腹膜增厚浑浊伴多发结节。肝脏大小、形态正常，肝内密度均匀，未见局灶性密度异常，肝内血管走行正常，肝内外胆管无扩张，脾不大，胰腺大小形态及密度正常。两侧肾脏大小及形态密度正常。左侧肾上腺稍增粗，右侧肾上腺未见明显异常。腹膜后未见肿大淋巴结，腹腔内未见积液。横膈前、肝门、腹膜后稍大淋巴结。 卵巢癌探查术后化疗后，肝包膜、网膜、腹膜增厚浑浊伴多发结节，考虑转移。 横膈前、肝门、腹膜后稍大淋巴结，考虑转移可能。 左侧肾上腺稍增粗，请结合临床。&quot;
      },
      {
        &quot;report_id&quot;: &quot;2025-08-15|CT&quot;,
        &quot;date&quot;: &quot;2025-08-15T17:33:29&quot;,
        &quot;raw_text&quot;: &quot;盆腔内膀胱充盈良好，壁光滑均匀，子宫大小形态正常，密度均匀，双侧附件区囊实性肿块，增强扫描实性成分可见强化，大小约49×48mm。子宫直肠窝未见明显异常，腹膜后稍大淋巴结，盆腔微量积液。腹膜稍增厚浑浊。 卵巢癌探查术后化疗后，双侧附件区囊实性肿块，考虑MT。 腹膜稍增厚浑浊，腹膜后稍大淋巴结，转移可能。 盆腔微量积液。&quot;
      },
      {
        &quot;report_id&quot;: &quot;2025-08-19|CT&quot;,
        &quot;date&quot;: &quot;2025-08-19T11:01:40&quot;,
        &quot;raw_text&quot;: &quot;对比前片2025-6-4：肺动脉主干及其近端分支形态光整，未见明显充盈缺损或狭窄，两肺动脉远端分支充盈欠佳。 两侧胸廓对称，两肺纹理清晰，走向自然，右肺上叶见一微小结节约3mm，气管居中，所见各支气管腔通畅，两肺门及纵隔未见肿大淋巴结，胸膜无增厚，胸腔内无积液。横隔前组多发淋巴结较前缩小。 两肺动脉远端分支充盈欠佳和前相仿，肺动脉主干及其近端分支未见明显异常，请结合临床。 横膈前组多发淋巴结较前缩小。 右肺上叶微小结节。&quot;
      }
    ],
    &quot;oncologist&quot;: [],
    &quot;radiologist&quot;: [
      {
        &quot;report_id&quot;: &quot;2025-08-15|CT&quot;,
        &quot;date&quot;: &quot;2025-08-15T17:25:01&quot;,
        &quot;raw_text&quot;: &quot;肝包膜、网膜、腹膜增厚浑浊伴多发结节。肝脏大小、形态正常，肝内密度均匀，未见局灶性密度异常，肝内血管走行正常，肝内外胆管无扩张，脾不大，胰腺大小形态及密度正常。两侧肾脏大小及形态密度正常。左侧肾上腺稍增粗，右侧肾上腺未见明显异常。腹膜后未见肿大淋巴结，腹腔内未见积液。横膈前、肝门、腹膜后稍大淋巴结。 卵巢癌探查术后化疗后，肝包膜、网膜、腹膜增厚浑浊伴多发结节，考虑转移。 横膈前、肝门、腹膜后稍大淋巴结，考虑转移可能。 左侧肾上腺稍增粗，请结合临床。&quot;
      },
      {
        &quot;report_id&quot;: &quot;2025-08-15|CT&quot;,
        &quot;date&quot;: &quot;2025-08-15T17:33:29&quot;,
        &quot;raw_text&quot;: &quot;盆腔内膀胱充盈良好，壁光滑均匀，子宫大小形态正常，密度均匀，双侧附件区囊实性肿块，增强扫描实性成分可见强化，大小约49×48mm。子宫直肠窝未见明显异常，腹膜后稍大淋巴结，盆腔微量积液。腹膜稍增厚浑浊。 卵巢癌探查术后化疗后，双侧附件区囊实性肿块，考虑MT。 腹膜稍增厚浑浊，腹膜后稍大淋巴结，转移可能。 盆腔微量积液。&quot;
      },
      {
        &quot;report_id&quot;: &quot;2025-08-19|CT&quot;,
        &quot;date&quot;: &quot;2025-08-19T11:01:40&quot;,
        &quot;raw_text&quot;: &quot;对比前片2025-6-4：肺动脉主干及其近端分支形态光整，未见明显充盈缺损或狭窄，两肺动脉远端分支充盈欠佳。 两侧胸廓对称，两肺纹理清晰，走向自然，右肺上叶见一微小结节约3mm，气管居中，所见各支气管腔通畅，两肺门及纵隔未见肿大淋巴结，胸膜无增厚，胸腔内无积液。横隔前组多发淋巴结较前缩小。 两肺动脉远端分支充盈欠佳和前相仿，肺动脉主干及其近端分支未见明显异常，请结合临床。 横膈前组多发淋巴结较前缩小。 右肺上叶微小结节。&quot;
      }
    ],
    &quot;pathologist&quot;: [],
    &quot;nuclear&quot;: [
      {
        &quot;report_id&quot;: &quot;2025-08-15|CT&quot;,
        &quot;date&quot;: &quot;2025-08-15T17:25:01&quot;,
        &quot;raw_text&quot;: &quot;肝包膜、网膜、腹膜增厚浑浊伴多发结节。肝脏大小、形态正常，肝内密度均匀，未见局灶性密度异常，肝内血管走行正常，肝内外胆管无扩张，脾不大，胰腺大小形态及密度正常。两侧肾脏大小及形态密度正常。左侧肾上腺稍增粗，右侧肾上腺未见明显异常。腹膜后未见肿大淋巴结，腹腔内未见积液。横膈前、肝门、腹膜后稍大淋巴结。 卵巢癌探查术后化疗后，肝包膜、网膜、腹膜增厚浑浊伴多发结节，考虑转移。 横膈前、肝门、腹膜后稍大淋巴结，考虑转移可能。 左侧肾上腺稍增粗，请结合临床。&quot;
      },
      {
        &quot;report_id&quot;: &quot;2025-08-15|CT&quot;,
        &quot;date&quot;: &quot;2025-08-15T17:33:29&quot;,
        &quot;raw_text&quot;: &quot;盆腔内膀胱充盈良好，壁光滑均匀，子宫大小形态正常，密度均匀，双侧附件区囊实性肿块，增强扫描实性成分可见强化，大小约49×48mm。子宫直肠窝未见明显异常，腹膜后稍大淋巴结，盆腔微量积液。腹膜稍增厚浑浊。 卵巢癌探查术后化疗后，双侧附件区囊实性肿块，考虑MT。 腹膜稍增厚浑浊，腹膜后稍大淋巴结，转移可能。 盆腔微量积液。&quot;
      },
      {
        &quot;report_id&quot;: &quot;2025-08-19|CT&quot;,
        &quot;date&quot;: &quot;2025-08-19T11:01:40&quot;,
        &quot;raw_text&quot;: &quot;对比前片2025-6-4：肺动脉主干及其近端分支形态光整，未见明显充盈缺损或狭窄，两肺动脉远端分支充盈欠佳。 两侧胸廓对称，两肺纹理清晰，走向自然，右肺上叶见一微小结节约3mm，气管居中，所见各支气管腔通畅，两肺门及纵隔未见肿大淋巴结，胸膜无增厚，胸腔内无积液。横隔前组多发淋巴结较前缩小。 两肺动脉远端分支充盈欠佳和前相仿，肺动脉主干及其近端分支未见明显异常，请结合临床。 横膈前组多发淋巴结较前缩小。 右肺上叶微小结节。&quot;
      }
    ]
  },
  &quot;pathology&quot;: {
    &quot;chair&quot;: [],
    &quot;oncologist&quot;: [],
    &quot;radiologist&quot;: [],
    &quot;pathologist&quot;: [],
    &quot;nuclear&quot;: []
  },
  &quot;mutation&quot;: {
    &quot;chair&quot;: [],
    &quot;oncologist&quot;: [],
    &quot;radiologist&quot;: [],
    &quot;pathologist&quot;: [],
    &quot;nuclear&quot;: []
  }
}</pre>
  </details>

  <details class="mt">
    <summary>Global Guideline RAG</summary>
    <h3>RAG Query</h3>
    <pre>High‑grade bilateral adnexal adenocarcinoma (likely Müllerian, high‑grade endometrioid vs serous), platinum‑exposed, with peritoneal/omental/liver/lymph‑node metastases; gastric SM1 adenocarcinoma; MMR intact, HER2 0, ER partial+, WT1/PAX8+; mild cytopenias but no major organ dysfunction.</pre>
    <h3>Evidence Pack (top-k)</h3>
    <pre>RAG Evidence Pack (top=5):
[1] score=0.6319 esgo_eshre_esge_fertilitysparing_pocket_2025__v00000000 [PAGE 16]
    B Oncologic selection criteria acceptable in selected cases One of the following criteria should be met: •	 Low-grade serous and low-grade endometrioid carcinomas stage IC2; •	 Mucinous carcinoma expansile subtype stage IC3; •	 Clear cell carcinoma stage IC2; •	 High grade serous and high-grade endo…
[2] score=0.6298 nccn_ovariancancer_v3_2025__v00000000 [PAGE 11]
    4. C/A/P CT or MRI with contrast, PET/CT (skull base to mid-thigh), or PET as indicated. x No definitive evidence of disease. Grade 2 endometrioid Grade 3 endometrioid/ high-grade serous carcinomat Platinum-based chemotherapy (see primary regimens for stage II–IV disease [OV-C, 6 of 12])n,v PRIMARY…
[3] score=0.6260 esgo_ovariancancer_pocketguidelines_2025__v00000000 [PAGE 8]
    8 TABLE OF CONTENTS Pathology and molecular biology ...................................................................... 10 1. 	 Which molecular and genomic tests should be carried out  at diagnosis as prognostic or predictive markers for high-grade  tubo-ovarian carcinoma?........................…
[4] score=0.6183 esgo_esmo_esp_consensus_ovariancancer_2024__v00000000 [PAGE 6]
    carcinoma demonstrated that adjuvant platinum-based ChT prolonged survival, but did not prospectively evaluate his- tological subtypes.38,39 High-grade EC has a similar prog- nosis to HGSC and is worse than low-grade EC. It is not clear whether there is any survival beneﬁt for adjuvant ChT in stage …
[5] score=0.6172 esgo_eshre_esge_fertilitysparing_pocket_2025__v00000000 [PAGE 17]
    to the use of ovarian preservation itself and/or the natural history of the disease (whatever the preservation or not of the ovary) in these patients having poorest prognostic factors). 1non-invasive peritoneal implants; 2including immature teratoma, dysgerminoma, Yolk-sac tumours; 3well and moderat…</pre>
    <h3>RAG Raw Hits (JSON)</h3>
    <pre>[
  {
    &quot;rank&quot;: 1,
    &quot;score&quot;: 0.6319203972816467,
    &quot;doc_id&quot;: &quot;esgo_eshre_esge_fertilitysparing_pocket_2025__v00000000&quot;,
    &quot;page&quot;: 16,
    &quot;text&quot;: &quot;B\nOncologic selection criteria acceptable in selected cases\nOne of the following criteria should be met:\n•\t Low-grade serous and low-grade endometrioid carcinomas stage IC2;\n•\t Mucinous carcinoma expansile subtype stage IC3;\n•\t Clear cell carcinoma stage IC2;\n•\t High grade serous and high-grade endometrioid carcinomas stage IC2;\n•\t Mucinous carcinoma infiltrative stage IC1 and IC2;\n•\t Granulosa cell tumour stage IC2 and IC3;\n•\t Sertoli Leydig cell tumours, well differentiated and moderately differen-\n\ntiated at stages IB and IC1;\n•\t Tubo-ovarian carcinoma (unilateral) or serous tubal intraepithelial\n\ncarcinoma in patients younger than 40 years with high-risk predisposition\n\ngermline mutation.\nC&quot;
  },
  {
    &quot;rank&quot;: 2,
    &quot;score&quot;: 0.629806399345398,
    &quot;doc_id&quot;: &quot;nccn_ovariancancer_v3_2025__v00000000&quot;,
    &quot;page&quot;: 11,
    &quot;text&quot;: &quot;4. \u0007C/A/P CT or MRI with contrast, PET/CT (skull base to mid-thigh), or PET as\nindicated.\nx No definitive evidence of disease.\nGrade 2 endometrioid\nGrade 3 endometrioid/\nhigh-grade serous\ncarcinomat\nPlatinum-based\nchemotherapy\n(see primary\nregimens for stage\nII–IV disease [OV-C,\n6 of 12])n,v\nPRIMARY CHEMOTHERAPY/PRIMARY ADJUVANT THERAPYv\nProvide symptom\nmanagement and\nbest supportive care.\nRefer for palliative\ncare assessment, if\nappropriate.\n• See NCCN Guidelines\nfor Palliative Care\n• See NCCN Guidelines\nfor Survivorship\n• Provide symptom\nmanagement and\nbest supportive care.\nRefer for palliative\ncare assessment, if\nappropriate.\n\u0017See NCCN Guidelines\nfor Palliative Care\n\u0017See NCCN Guidelines\nfor Survivorship\nLCOC-1\nLess common ovarian cancers (LCOC), any stageo,u\nComplete\nResponse\n(CR)x/Partial\nResponse (PR)\nStable disease\nor progression\nTherapy for Persistent\nDisease or Recurrence\n(OV-7)\nImaginga\nas clinically\nindicated:\neg, C/A/P CT, chest\nCT, A/P MRI, PET/\nMRI, PET/CT (skull\nbase to mid-thigh)\nPLEASE NOTE that use of this NCCN Content is governed by the End-User License Agreement, and you MAY NOT distribute this Content or use it with any artificial intelligence model or tool.&quot;
  },
  {
    &quot;rank&quot;: 3,
    &quot;score&quot;: 0.6260233521461487,
    &quot;doc_id&quot;: &quot;esgo_ovariancancer_pocketguidelines_2025__v00000000&quot;,
    &quot;page&quot;: 8,
    &quot;text&quot;: &quot;8\nTABLE OF CONTENTS\nPathology and molecular biology ...................................................................... 10\n1. \t Which molecular and genomic tests should be carried out\n\nat diagnosis as prognostic or predictive markers for high-grade\n\ntubo-ovarian carcinoma?.............................................................................. 10\n2. \t What is the role of circulating and tissue biomarkers during treatment\n\nand follow-up?............................................................................................. 10\n3. \t How should low-grade serous carcinoma (LGSC) and high-grade serous\n\ncarcinoma (HGSC) be diagnosed?................................................................. 11\n4. \t What is the role of molecular classification in ovarian endometrioid\n\ncarcinoma (EC) and clear-cell carcinoma (CCC)?............................................ 12\nEarly-stage disease and pelvic mass in pregnancy ........................................... 12\n5. \t How should an adnexal mass be managed in pregnant women?.................. 12\n6. \t How should an adnexal mass be managed for women who want to retain&quot;
  },
  {
    &quot;rank&quot;: 4,
    &quot;score&quot;: 0.618280291557312,
    &quot;doc_id&quot;: &quot;esgo_esmo_esp_consensus_ovariancancer_2024__v00000000&quot;,
    &quot;page&quot;: 6,
    &quot;text&quot;: &quot;carcinoma demonstrated that adjuvant platinum-based ChT\nprolonged survival, but did not prospectively evaluate his-\ntological subtypes.38,39 High-grade EC has a similar prog-\nnosis to HGSC and is worse than low-grade EC. It is not clear\nwhether there is any survival beneﬁt for adjuvant ChT in\nstage IA or IB CCC.40,41\nRecommendation\n7.1:\nComplete\nsurgical\nresection\nincluding total abdominal hysterectomy, bilateral salpingo-\noophorectomy, omentectomy, systematic pelvic and para-\naortic lymph node dissection, peritoneal biopsies and\ncytological analysis should be the standard surgical pro-\ncedure in stage I-II high-grade EC, CCC and high-risk\nmucinous ovarian carcinoma [IV, A].\nConsensus: 97% (38) yes, 3% (1) no, 0% (0) abstain (39\nvoters)\nRecommendation 7.2: Patients with stage I-II high-grade\nEC should be offered adjuvant platinum-based ChT [IV, A].\nConsensus: 100% (39) yes, 0% (0) no, 0% (0) abstain (39\nvoters)\nRecommendation 7.3: Adjuvant ChT may be omitted for\nadequately staged IA or IB CCC [IV, C].\nConsensus: 90% (35) yes, 5% (2) no, 5% (2) abstain (39\nvoters)\nRecommendation 7.4: Adjuvant ChT may be considered\nfor stage IC1 CCC [IV, C].&quot;
  },
  {
    &quot;rank&quot;: 5,
    &quot;score&quot;: 0.6171758770942688,
    &quot;doc_id&quot;: &quot;esgo_eshre_esge_fertilitysparing_pocket_2025__v00000000&quot;,
    &quot;page&quot;: 17,
    &quot;text&quot;: &quot;to the use of ovarian preservation itself and/or the natural history of the disease (whatever\nthe preservation or not of the ovary) in these patients having poorest prognostic factors).\n1non-invasive peritoneal implants; 2including immature teratoma, dysgerminoma, Yolk-sac\ntumours; 3well and moderately differentiated; 4poorly differentiated; #for grade 2-3 imma-\nture teratoma stage II-IV, fertility-sparing data are limited; ## for Sertoli-Leydig cell tumour\nstage IC2-3, fertility-sparing data are limited.\nBOT borderline ovarian tumour; CCC clear cell carcinoma; GCT germ cell tumour; GrCT\ngranulosa cell tumour; HGEC high-grade endometrioid carcinoma; HGSC high-grade serous\ncarcinoma; LGSC low-grade serous carcinoma; LGEC low-grade endometrioid carcinoma,\nMCexp mucinous carcinoma with expansile invasion, MCinf mucinous carcinoma with in-\nfiltrative invasion; SCC small cell carcinoma; SLCT Sertoli-Leydig cell tumour.&quot;
  }
]</pre>
    <h3>Digest (<=8 bullets)</h3>
    <pre>- Fertility-sparing surgery *may be considered* in highly selected epithelial ovarian cancers if all of the following are met: comprehensive staging, unilateral disease, and histology/stage such as: low‑grade serous or low‑grade endometrioid stage IC2; mucinous expansile subtype stage IC3; clear cell stage IC2; or high‑grade serous/endometrioid stage IA–IC1 confined to the ovary, with counselling on higher relapse risk [esgo_eshre_esge_fertilitysparing_pocket_2025__v00000000].

- In fertility-sparing approaches, preservation is usually limited to the uterus and one ovary/tube, with complete staging including peritoneal cytology, omentectomy/biopsies, peritoneal biopsies, and lymph node assessment as indicated, and clear documentation that the contralateral ovary appears normal [esgo_eshre_esge_fertilitysparing_pocket_2025__v00000000].

- Fertility-sparing management is generally *not recommended* for high‑grade serous or high‑grade endometrioid carcinomas beyond stage IC1 or when extra‑ovarian disease is present, because of poor prognosis and higher recurrence risk [esgo_eshre_esge_fertilitysparing_pocket_2025__v00000000].

- Adjuvant platinum-based chemotherapy improves survival in early-stage epithelial ovarian cancer overall, but data do not definitively show a survival benefit in all stage I subgroups; high‑grade endometrioid cancers have a prognosis similar to high‑grade serous and are usually managed with adjuvant chemotherapy when stage IC or higher [esgo_esmo_esp_consensus_ovariancancer_2024__v00000000].

- For early-stage grade 3 endometrioid or high‑grade serous epithelial ovarian cancers after complete staging and no macroscopic residual disease, NCCN recommends platinum-based combination chemotherapy per stage II–IV primary regimens (e.g., carboplatin/paclitaxel) [nccn_ovariancancer_v3_2025__v00000000].

- Postoperative imaging (CT/MRI with contrast or PET/CT) can be used selectively to confirm absence of residual or metastatic disease when findings will change adjuvant treatment decisions or fertility-sparing considerations [nccn_ovariancancer_v3_2025__v00000000].

- For malignant ovarian germ cell tumours and sex cord–stromal tumours, fertility-sparing surgery is standard in early stages if staging is adequate; long-term follow-up is essential because late recurrences can occur, independent of ovarian preservation [esgo_eshre_esge_fertilitysparing_pocket_2025__v00000000].

- Patients considered for conservative management must receive detailed counselling on oncologic risks, need for close surveillance, and potential requirement for completion surgery after childbearing, with documentation of shared decision-making [esgo_eshre_esge_fertilitysparing_pocket_2025__v00000000].</pre>
  </details>

  <details class='mt' open><summary>Pipeline Flow (Mermaid)</summary><pre class='mermaid'>flowchart TD
  A[Load Case + Fingerprint] --&gt; B[Load Reports]
  B --&gt; C[Report Selection per Role]
  C --&gt; D[Global Guideline RAG]
  D --&gt; E[Init Specialist Agents]
  E --&gt; F[MDT Discussion Engine]
  F --&gt; G[Trial Matching]
  G --&gt; H[Final Chair Output]
  H --&gt; I[Save Logs]
</pre></details>

  <details class="mt">
    <summary>Trace Events (JSON)</summary>
    <pre>[
  {
    &quot;ts&quot;: &quot;2026-01-17T22:31:04.532778&quot;,
    &quot;event&quot;: &quot;pipeline_start&quot;,
    &quot;payload&quot;: {
      &quot;visit_time&quot;: &quot;2025-09-22 14:14:50.183000&quot;,
      &quot;meta_info&quot;: &quot;341621197711091961&quot;
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-17T22:31:04.533134&quot;,
    &quot;event&quot;: &quot;case_fingerprint&quot;,
    &quot;payload&quot;: {
      &quot;case_fingerprint&quot;: &quot;2cb3272105d4&quot;
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-17T22:31:04.789425&quot;,
    &quot;event&quot;: &quot;reports_loaded&quot;,
    &quot;payload&quot;: {
      &quot;lab_n&quot;: 57,
      &quot;img_n&quot;: 4,
      &quot;path_n&quot;: 0,
      &quot;mut_n&quot;: 0,
      &quot;cutoff_dt&quot;: &quot;2025-09-23 14:14:50&quot;
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-17T22:31:15.993160&quot;,
    &quot;event&quot;: &quot;reports_selected&quot;,
    &quot;payload&quot;: {
      &quot;lab&quot;: {
        &quot;chair&quot;: [
          &quot;20250818|9701134|2025-08-18&quot;,
          &quot;20250902|8300228|2025-09-02&quot;,
          &quot;20250923|5601694|2025-09-23&quot;
        ],
        &quot;oncologist&quot;: [
          &quot;20250818|9701134|2025-08-18&quot;,
          &quot;20250907|10100012|2025-09-07&quot;,
          &quot;20250923|5601694|2025-09-23&quot;
        ],
        &quot;radiologist&quot;: [],
        &quot;pathologist&quot;: [],
        &quot;nuclear&quot;: []
      },
      &quot;imaging&quot;: {
        &quot;chair&quot;: [
          &quot;2025-06-04|CT|2025-06-04&quot;,
          &quot;2025-08-15|CT|2025-08-15&quot;,
          &quot;2025-08-15|CT|2025-08-15&quot;,
          &quot;2025-08-19|CT|2025-08-19&quot;
        ],
        &quot;oncologist&quot;: [],
        &quot;radiologist&quot;: [
          &quot;2025-08-15|CT|2025-08-15&quot;,
          &quot;2025-08-15|CT|2025-08-15&quot;,
          &quot;2025-08-19|CT|2025-08-19&quot;
        ],
        &quot;pathologist&quot;: [],
        &quot;nuclear&quot;: [
          &quot;2025-08-15|CT|2025-08-15&quot;,
          &quot;2025-08-15|CT|2025-08-15&quot;,
          &quot;2025-08-19|CT|2025-08-19&quot;
        ]
      },
      &quot;pathology&quot;: {
        &quot;chair&quot;: [],
        &quot;oncologist&quot;: [],
        &quot;radiologist&quot;: [],
        &quot;pathologist&quot;: [],
        &quot;nuclear&quot;: []
      },
      &quot;mutation&quot;: {
        &quot;chair&quot;: [],
        &quot;oncologist&quot;: [],
        &quot;radiologist&quot;: [],
        &quot;pathologist&quot;: [],
        &quot;nuclear&quot;: []
      }
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-17T22:31:27.813787&quot;,
    &quot;event&quot;: &quot;rag_query&quot;,
    &quot;payload&quot;: {
      &quot;query&quot;: &quot;High‑grade bilateral adnexal adenocarcinoma (likely Müllerian, high‑grade endometrioid vs serous), platinum‑exposed, with peritoneal/omental/liver/lymph‑node metastases; gastric SM1 adenocarcinoma; MMR intact, HER2 0, ER partial+, WT1/PAX8+; mild cytopenias but no major organ dysfunction.&quot;
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-17T22:31:27.813795&quot;,
    &quot;event&quot;: &quot;rag_hits&quot;,
    &quot;payload&quot;: {
      &quot;topk&quot;: 5,
      &quot;n&quot;: 5
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-17T22:31:42.148719&quot;,
    &quot;event&quot;: &quot;mdt_discussion_start&quot;,
    &quot;payload&quot;: {
      &quot;num_rounds&quot;: 2,
      &quot;num_turns&quot;: 2
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-17T22:35:38.445424&quot;,
    &quot;event&quot;: &quot;mdt_discussion_end&quot;,
    &quot;payload&quot;: {
      &quot;merged_chars&quot;: 3348
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-17T22:35:38.446470&quot;,
    &quot;event&quot;: &quot;final_output_start&quot;,
    &quot;payload&quot;: {}
  },
  {
    &quot;ts&quot;: &quot;2026-01-17T22:35:42.226736&quot;,
    &quot;event&quot;: &quot;final_output_end&quot;,
    &quot;payload&quot;: {
      &quot;final_output_chars&quot;: 858
    }
  }
]</pre>
  </details>

</body>
</html>
